ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) for the period between March 10, 2024, and September 29, 2025, due to alleged misleading statements and failure to disclose material facts regarding the company's products [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, defendants made false and/or misleading statements about the differences between Nanobodies and monoclonal antibodies, specifically regarding SLK and BIMZELX [5]. - Allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's Nanobody structure does not provide superior clinical benefits over traditional monoclonal antibodies [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [5]. Group 2: Participation Information - Investors who purchased MoonLake common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].